Amneal Pharmaceuticals, Inc. AMRX Specialty — Operating Income (Loss)

Other segment segments

Similar metrics at other companies

BCPCSpecialty Products — Operating Income (Loss)

$11.94M+24.5%

APGSpecialty Services — Operating Income (Loss)

$39M+34.5%

GTLSSpecialty Products — Operating Income (Loss)

$8.4M-82.6%

THGSpecialty Lines — Operating Income

$84M+30.0%

MLMSpecialties — Operating Income

$35M+6.1%

CHDSpecialty Products Division — Operating Income

$10.9M-14.8%

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s specialty — operating income (loss)?

Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — operating income (loss) of $50.06M in Q1 2026.

How has Amneal Pharmaceuticals, Inc.'s specialty — operating income (loss) changed year-over-year?

Amneal Pharmaceuticals, Inc.'s specialty — operating income (loss) increased by 233.9% year-over-year, from $14.99M to $50.06M.

What does specialty — operating income (loss) mean?

Measures the core profitability of the specialty segment by subtracting operating expenses from gross profit. It is a primary indicator of the segment's ability to generate sustainable earnings from its proprietary pharmaceutical portfolio.